There are several variables in determining best time to up list. In my opinion "momentum" is the most important, even more important than the pps, assuming that the pps is at least .20 cents.

I think Gerald wants institutional investors investing in AMBS in February as Lympro starts it's revenue ascent upwards. Institutional investors could help build momentum at just the right time, but they can't invest unless we're on NASDAQ. So it's a chicken or the egg question, which comes first?

Reverse splits don't hurt if you have new revenue and momentum. Personally, I'd rather up list in February at .25 cents than wait until June, just to try to make the RS smaller.